Alife Health (“Alife”), a leading fertility technology company specializing in the development of AI tools for in vitro fertilization (IVF), has announced a groundbreaking partnership with Boston IVF, a leading fertility clinic with more than 25 locations across the U.S., to pilot the country’s first AI tool for IVF medication optimization. Boston IVF will implement Alife’s Stim Assist software, which is designed to help IVF clinicians retrieve the optimal number of eggs for each patient and reduce overall medication costs.

The collaboration aims to advance the field of reproductive medicine by combining Alife’s state-of-the-art AI technology with the expertise of Boston IVF’s world-renowned fertility specialists. By leveraging advanced machine learning algorithms, they hope to enhance the accuracy of IVF treatment protocols, ultimately improving the success rates for couples trying to conceive through assisted reproductive technologies.

“Our partnership with Alife marks a major milestone in the advancement of AI technology for fertility treatment,” says David Stern, CEO of Boston IVF. “At Boston IVF, we are always looking for new cutting-edge technologies to research, test, and integrate into our practices to provide the best possible care for our patients. By exploring the potential that AI technology can bring to our field, we aim to establish a new standard for IVF and continue to bring hope to millions of couples struggling with infertility.”

Alife’s Stim Assist software draws on data from tens of thousands of historical IVF patient cycles to generate data-driven insights. These insights can help clinicians understand what treatment has produced the best outcomes for similar patients, giving them the power to design a personalized treatment protocol, backed by data. The partnership will allow Boston IVF's team of experienced fertility specialists to integrate Alife's AI software into their practice, providing their patients with innovative and effective solutions.

“Boston IVF, with its extensive network of fertility clinics and a long-standing reputation for excellence in reproductive medicine, was a natural choice for this collaboration,” says Paxton Maeder-York, CEO and founder of Alife. “Our past research has shown that using our Stim Assist software has produced improvements in both patient egg yield and cost savings. We couldn’t be more excited to partner with this storied institution as we pilot this software to demonstrate the immense promise that AI presents for the IVF industry.”